A single PFE.N) coronavirus vaccine (PFE.N) may not produce an adequate immune response to protect against the dominant new strains except in people already infected with COVID-19, according to a UK study at Published Friday
A study led by Imperial College, which looked at the immune response of UK healthcare workers after the first Pfizer injection, found that people who had previously had a mild or asymptomatic infection. Added protection from an increasingly infectious form of mutation that occurs in the UK and South Africa.
But the immune response after the first injection is reduced in people who have never been infected, which could put them at risk from that variant.
“This study highlights the importance of getting a second dose of the vaccine to protect the population,” said Rosemary Boyton, Imperial Professor of Immunology and Respiratory Medicine, who led the study.
“People who received the first vaccine and who have never been infected with SARS-COV-2 will not be fully protected from ‘Diverse concerns’
Research published in the journal Science analyzed blood samples for the presence and levels of immunity against the original SARS-CoV-2 strain, including a UK variant called B.1.1.7 and another. The one known as B.1.351 originated in South Africa.
It found that after initial exposure to Pfizer vaccine, increased immune responses in the form of T-cells, B-cells and neutralized antibodies were associated with previous infections.
However, in people who have never had COVID-19, a single vaccination results in decreased levels of neutralizing antibodies against the original virus and the mutated strains.
Danny Altmann, an imperial immunology professor who co-led the study, said this means that there will be “loopholes” for people during the first and second dosing.
Our Standard: The Thomson Reuters Trust Principle.